vs
Side-by-side financial comparison of Pacira BioSciences, Inc. (PCRX) and Porch Group, Inc. (PRCH). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $121.1M, roughly 1.5× Porch Group, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -3.9%, a 5.5% gap on every dollar of revenue. On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs 5.0%). Over the past eight quarters, Porch Group, Inc.'s revenue compounded faster (26.4% CAGR vs -0.2%).
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
PCRX vs PRCH — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $177.4M | $121.1M |
| Net Profit | $2.9M | $-4.7M |
| Gross Margin | — | 52.7% |
| Operating Margin | 3.9% | 34.7% |
| Net Margin | 1.6% | -3.9% |
| Revenue YoY | 5.0% | 100.0% |
| Net Profit YoY | — | 2.0% |
| EPS (diluted) | $0.07 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $177.4M | $121.1M | ||
| Q4 25 | $196.9M | $112.3M | ||
| Q3 25 | $179.5M | $115.1M | ||
| Q2 25 | $181.1M | $107.0M | ||
| Q1 25 | $168.9M | $84.5M | ||
| Q4 24 | $187.3M | $75.3M | ||
| Q3 24 | $168.6M | $77.7M | ||
| Q2 24 | $178.0M | $75.9M |
| Q1 26 | $2.9M | $-4.7M | ||
| Q4 25 | — | $-3.5M | ||
| Q3 25 | $5.4M | $-10.9M | ||
| Q2 25 | $-4.8M | $2.6M | ||
| Q1 25 | $4.8M | $8.4M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | $-143.5M | $14.4M | ||
| Q2 24 | $18.9M | $-64.3M |
| Q1 26 | — | 52.7% | ||
| Q4 25 | 79.5% | 99.5% | ||
| Q3 25 | 80.9% | 75.6% | ||
| Q2 25 | 77.4% | 70.9% | ||
| Q1 25 | 79.7% | 77.4% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | 79.4% | ||
| Q2 24 | 75.1% | 22.1% |
| Q1 26 | 3.9% | 34.7% | ||
| Q4 25 | 1.2% | 14.7% | ||
| Q3 25 | 3.5% | 14.2% | ||
| Q2 25 | 4.7% | 4.7% | ||
| Q1 25 | 1.2% | -1.5% | ||
| Q4 24 | 13.2% | 33.3% | ||
| Q3 24 | -82.8% | -3.2% | ||
| Q2 24 | 15.9% | -69.2% |
| Q1 26 | 1.6% | -3.9% | ||
| Q4 25 | — | -3.1% | ||
| Q3 25 | 3.0% | -9.4% | ||
| Q2 25 | -2.7% | 2.4% | ||
| Q1 25 | 2.8% | 9.9% | ||
| Q4 24 | — | 40.5% | ||
| Q3 24 | -85.1% | 18.5% | ||
| Q2 24 | 10.6% | -84.8% |
| Q1 26 | $0.07 | $-0.04 | ||
| Q4 25 | $0.05 | $0.00 | ||
| Q3 25 | $0.12 | $-0.10 | ||
| Q2 25 | $-0.11 | $0.00 | ||
| Q1 25 | $0.10 | $0.07 | ||
| Q4 24 | $0.38 | $0.34 | ||
| Q3 24 | $-3.11 | $0.12 | ||
| Q2 24 | $0.39 | $-0.65 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $144.3M | $68.4M |
| Total DebtLower is stronger | — | $391.3M |
| Stockholders' EquityBook value | $653.9M | $26.3M |
| Total Assets | $1.2B | $806.6M |
| Debt / EquityLower = less leverage | — | 14.87× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $144.3M | $68.4M | ||
| Q4 25 | $238.4M | $57.3M | ||
| Q3 25 | $246.3M | $85.0M | ||
| Q2 25 | $445.9M | $79.8M | ||
| Q1 25 | $493.6M | $70.4M | ||
| Q4 24 | $484.6M | $191.7M | ||
| Q3 24 | $453.8M | $238.6M | ||
| Q2 24 | $404.2M | $308.4M |
| Q1 26 | — | $391.3M | ||
| Q4 25 | $372.2M | $392.8M | ||
| Q3 25 | $376.7M | $387.1M | ||
| Q2 25 | $580.5M | $394.1M | ||
| Q1 25 | $583.4M | $409.2M | ||
| Q4 24 | $585.3M | $403.9M | ||
| Q3 24 | — | $399.0M | ||
| Q2 24 | — | $436.8M |
| Q1 26 | $653.9M | $26.3M | ||
| Q4 25 | $693.1M | $-24.6M | ||
| Q3 25 | $727.2M | $-27.9M | ||
| Q2 25 | $757.8M | $-29.3M | ||
| Q1 25 | $798.5M | $-52.4M | ||
| Q4 24 | $778.3M | $-43.2M | ||
| Q3 24 | $749.6M | $-77.0M | ||
| Q2 24 | $879.3M | $-101.9M |
| Q1 26 | $1.2B | $806.6M | ||
| Q4 25 | $1.3B | $797.4M | ||
| Q3 25 | $1.3B | $787.7M | ||
| Q2 25 | $1.5B | $770.7M | ||
| Q1 25 | $1.6B | $802.3M | ||
| Q4 24 | $1.6B | $814.0M | ||
| Q3 24 | $1.5B | $867.3M | ||
| Q2 24 | $1.6B | $876.1M |
| Q1 26 | — | 14.87× | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PRCH
Segment breakdown not available.
